Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

DLL3-targeted antibody-drug conjugate

DRUG CLASS:

DLL3-targeted antibody-drug conjugate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

rovalpituzumab tesirine (5)

rovalpituzumab tesirine (5)

›

DLL3 overexpression	Small Cell Lung Cancer	DLL3 overexpression	Small Cell Lung Cancer	rovalpituzumab tesirine Sensitive: B - Late Trials rovalpituzumab tesirine Sensitive : B	rovalpituzumab tesirine Sensitive: B - Late Trials rovalpituzumab tesirine Sensitive : B
DLL3 overexpression	Neuroendocrine Tumor	DLL3 overexpression	Neuroendocrine Tumor	rovalpituzumab tesirine Sensitive: C3 – Early Trials rovalpituzumab tesirine Sensitive : C3	rovalpituzumab tesirine Sensitive: C3 – Early Trials rovalpituzumab tesirine Sensitive : C3
DLL3 expression	Merkel Cell Carcinoma	DLL3 expression	Merkel Cell Carcinoma	rovalpituzumab tesirine Sensitive: C4 – Case Studies rovalpituzumab tesirine Sensitive : C4	rovalpituzumab tesirine Sensitive: C4 – Case Studies rovalpituzumab tesirine Sensitive : C4
DLL3 underexpression	Neuroblastoma	DLL3 underexpression	Neuroblastoma	rovalpituzumab tesirine Sensitive: D – Preclinical rovalpituzumab tesirine Sensitive : D	rovalpituzumab tesirine Sensitive: D – Preclinical rovalpituzumab tesirine Sensitive : D
DLL3 expression	Neuroblastoma	DLL3 expression	Neuroblastoma	rovalpituzumab tesirine Sensitive: D – Preclinical rovalpituzumab tesirine Sensitive : D	rovalpituzumab tesirine Sensitive: D – Preclinical rovalpituzumab tesirine Sensitive : D